Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1609679

registered interest
date	14/04/2023
answering body	Department for Business and Trade
answering dept id	214
answering dept short name	Business and Trade
answering dept sort name	Business and Trade
hansard heading	Home Office: Junior Ministers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business and Trade, whether she plans to appoint a Parliamentary Under-Secretary of State for Exports.
tabling member constituency	Gordon
tabling member printed	Richard Thomson
uin	179812
answer	answer is ministerial correction date of answer 18/05/2023 answer text <p>Lord Offord of Garvel was appointed Parliamentary Under Secretary of State in the Department of Business and Trade on 24 April 2023.</p><p>Ministerial responsibilities can be found here: https://www.gov.uk/government/organisations/department-for-business-and-trade.</p> answering member constituency Mid Worcestershire answering member printed Nigel Huddleston question first answered 18/05/2023 15:19:59 answering member 4407 label Biography information for Nigel Huddleston
tabling member	4796 label Biography information for Richard Thomson

1609680

registered interest
date	14/04/2023
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Meat: Origin Marking
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Environment, Food and Rural Affairs, whether her Department has made an assessment of the potential merits of making it a requirement for businesses selling food for consumption outside of homes, for example restaurants and takeaways, to notify consumers of the country of origin meat products.
tabling member constituency	Gordon
tabling member printed	Richard Thomson
uin	179813
answer	answer is ministerial correction date of answer 20/04/2023 answer text <p>Food Information to Consumers Regulations apply to all food sold on the UK market, including imported food, and require many foods to declare the origin on the label. For food that is sold out of home, while origin information is not mandatory, it is unlawful to mislead consumers as to the origin of the food or any specific ingredient, and there are no barriers to British meat being labelled as British.</p> answering member constituency Sherwood answering member printed Mark Spencer question first answered 20/04/2023 15:49:57 answering member 4055 label Biography information for Sir Mark Spencer
tabling member	4796 label Biography information for Richard Thomson

1609681

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he is taking steps to ensure awareness of metastatic breast cancer among NHS staff involved in primary care.
tabling member constituency	Halifax
tabling member printed	Holly Lynch
uin	179814
answer	answer is ministerial correction date of answer 25/04/2023 answer text <p>In April 2020, NHS England introduced the 'early cancer diagnosis service specification' for Primary Care Networks (PCNs), which 99% of general practices (GPs) are signed up to. This is designed to support improvements in rates of early cancer diagnosis by requiring PCNs to review the quality of their practices’ referrals for suspected cancer and take steps to improve this.</p><p>NHS England is supporting GPs to diagnose more cancers early by making funding available to embed clinical decision support tools within general practice. These tools are designed to support GPs in clinical decision making, such as whether to refer or request further diagnostic investigation in patients where they believe there is a risk of cancer, and identifying patients who may be at risk of cancer based on the symptoms they present with.</p><p>Cancer education programmes such as ‘Gateway C’ are available online and include specific courses on breast cancer, and face-to-face education sessions have now resumed and are offered by a range of providers.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 25/04/2023 11:47:39 answering member 4527 label Biography information for Helen Whately
tabling member	4472 label Biography information for Holly Lynch

1609682

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that all patients with primary breast cancer have an end of treatment summary in order to speed up detection of secondary breast cancer.
tabling member constituency	Halifax
tabling member printed	Holly Lynch
uin	179815
answer	answer is ministerial correction date of answer 20/04/2023 answer text <p>The NHS Long Term Plan states that, where appropriate, every person diagnosed with cancer will have access to personalised care, including a needs assessment, a care plan and health and wellbeing information and support. This includes provision of end of treatment summaries, empowering people to manage their care and the impact of their cancer.</p><p>The introduction of tailored follow up pathways for people after their initial breast cancer treatment has ensured there are clear access points for people with worrying symptoms or concerns to speak immediately to someone in the cancer team. Breast cancer-tailored follow up, which includes ‘patient initiated follow up’ or ‘open access follow up’ for suitable patients, is now in place in 95% of trusts.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 20/04/2023 09:55:22 answering member 4527 label Biography information for Helen Whately
tabling member	4472 label Biography information for Holly Lynch

1609683

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that data is collected to find out the number of patients living with metastatic breast cancer.
tabling member constituency	Halifax
tabling member printed	Holly Lynch
uin	179816
answer	answer is ministerial correction date of answer 24/04/2023 answer text <p>The National Cancer Registration and Analysis Service works closely with hospital trusts to determine sources of data which can be used to complete the Cancer Outcomes and Services Dataset data and also works with the software suppliers of cancer management systems to ensure that data items are able to be recorded. Compliance with data standards is monitored by local integrated care boards (ICBs).</p><p>The Healthcare Quality Improvement Partnership commissions, develops, and manages the National Clinical Audit and Patient Outcomes Programme, on behalf of NHS England, Wales and other devolved administrations. These audits have been introduced to reduce variation in treatment by demonstrating where care is being provided in line with standards and where a service is doing well or could be improved. Five additional new clinical audits were announced in May 2021, one of which will focus on metastatic breast cancer.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 179817 question first answered 24/04/2023 16:56:49 answering member 4527 label Biography information for Helen Whately
tabling member	4472 label Biography information for Holly Lynch

1609684

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that data is collected to assess the success rates of metastatic breast cancer treatment pathways.
tabling member constituency	Halifax
tabling member printed	Holly Lynch
uin	179817
answer	answer is ministerial correction date of answer 24/04/2023 answer text <p>The National Cancer Registration and Analysis Service works closely with hospital trusts to determine sources of data which can be used to complete the Cancer Outcomes and Services Dataset data and also works with the software suppliers of cancer management systems to ensure that data items are able to be recorded. Compliance with data standards is monitored by local integrated care boards (ICBs).</p><p>The Healthcare Quality Improvement Partnership commissions, develops, and manages the National Clinical Audit and Patient Outcomes Programme, on behalf of NHS England, Wales and other devolved administrations. These audits have been introduced to reduce variation in treatment by demonstrating where care is being provided in line with standards and where a service is doing well or could be improved. Five additional new clinical audits were announced in May 2021, one of which will focus on metastatic breast cancer.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 179816 question first answered 24/04/2023 16:56:49 answering member 4527 label Biography information for Helen Whately
tabling member	4472 label Biography information for Holly Lynch

1609685

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he is taking steps to speed up the drug approval process for new metastatic breast cancer treatments.
tabling member constituency	Halifax
tabling member printed	Holly Lynch
uin	179818
answer	answer is ministerial correction date of answer 25/04/2023 answer text <p>The Government is committed to supporting timely patient access to clinically- and cost-effective new drugs, including for metastatic breast cancer.</p><p>The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE) and NHS England are working closely together to ensure that there is a joined-up, timely approach to supporting access to new medicines for National Health Service patients, including those licensed through Project Orbis and the Innovative Licensing and Access Pathway. NICE is also able to make recommendations through the cancer drugs fund (CDF), which has benefitted over 88,000 patients as of March 2023. The CDF has allowed patients with metastatic breast cancer to access new medicines like trastuzumab, deruxtecan and palbociclib, while allowing for the collection of further data on their clinical- and cost-effectiveness to inform a final NICE recommendation.</p> answering member constituency Colchester answering member printed Will Quince question first answered 25/04/2023 12:24:50 answering member 4423 label Biography information for Will Quince
tabling member	4472 label Biography information for Holly Lynch

1609686

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the NHS has flexible and effective procedures for identifying the correct treatments for patients with metastatic breast cancer.
tabling member constituency	Halifax
tabling member printed	Holly Lynch
uin	179819
answer	answer is ministerial correction date of answer 20/04/2023 answer text <p>People with breast cancer are cared for by a team of healthcare professionals, each with their own expertise. This is known as the multidisciplinary team (MDT). Each MDT should include the full range of health professionals required to best inform and plan the most appropriate treatment options for the patient including for those patients with metastatic breast cancer. This would include appropriate surgeons, oncologists and clinicians from a wide range of other disciplines including nursing, radiology and pathology.</p><p>NHS England expects treating clinicians will consider all available treatment options, taking account of relevant clinical and professional guidelines and the individual needs of the patient. In all cases, discussions about treatment options should take place in line with the General Medical Council’s Decision Making and Consent Guidance to ensure that people can make an informed choice about their treatment.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 20/04/2023 09:59:06 answering member 4527 label Biography information for Helen Whately
tabling member	4472 label Biography information for Holly Lynch

1609687

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he is taking steps to ensure that the National Institute for Clinical Excellence and the Scottish Medicines Consortium collaborate effectively on drug approvals for metastatic breast cancer treatment.
tabling member constituency	Halifax
tabling member printed	Holly Lynch
uin	179820
answer	answer is ministerial correction date of answer 20/04/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is committed to publishing draft recommendations on all newly licensed treatments around the time of licensing in England and works closely with the Medicines and Healthcare products Regulatory Agency (MHRA) to ensure that licensing procedures and health technology assessments are as streamlined as possible.</p><p>Both NICE and the Scottish Medicines Consortium are permanent partners in the Innovative Licensing and Access Pathway which supports more rapid review and approval of promising new cancer treatments.</p><p>NICE is an England-only body. Health is a devolved matter and as such decisions on access to drugs in Scotland is a matter for the devolved Government.</p> answering member constituency Colchester answering member printed Will Quince question first answered 20/04/2023 09:06:59 answering member 4423 label Biography information for Will Quince
tabling member	4472 label Biography information for Holly Lynch

1609688

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to take steps to ensure as far as possible that access to clinical trials for treatment of metastatic breast cancer is open to patients (a) from all areas of the UK (b) regardless of line of therapy restrictions and (c) who have pre-existing conditions.
tabling member constituency	Halifax
tabling member printed	Holly Lynch
uin	179821
answer	answer is ministerial correction date of answer 21/04/2023 answer text <p>The Government published ‘Saving and Improving Lives: The Future of UK Clinical Research Delivery’ in March 2021. The phase two implementation plan for the vision, published in June 2021, aims to make it easier for all patients<strong>,</strong> including cancer patients<strong>,</strong> to access relevant research.</p><p>The National Institute for Health and Care Research (NIHR) infrastructure supports clinical research, including metastatic breast cancer. The NIHR Clinical Research Network includes 15 Local Clinical Research Networks, accessible across all geographies in England, including underserved regions and communities. The NIHR also provides the online platform 'Be Part of Research' allowing users to search and register interest in research studies relevant to them across the United Kingdom.</p> answering member constituency Colchester answering member printed Will Quince question first answered 21/04/2023 10:49:39 answering member 4423 label Biography information for Will Quince
tabling member	4472 label Biography information for Holly Lynch